Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Assets: 2013-2024

Historic Assets for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $457.9 million.

  • Ocular Therapeutix's Assets fell 16.21% to $410.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $410.9 million, marking a year-over-year decrease of 16.21%. This contributed to the annual value of $457.9 million for FY2024, which is 81.68% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Assets of $457.9 million as of FY2024, which was up 81.68% from $252.1 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Assets ranged from a high of $457.9 million in FY2024 and a low of $149.3 million during FY2022.
  • Over the past 3 years, Ocular Therapeutix's median Assets value was $252.1 million (recorded in 2023), while the average stood at $286.4 million.
  • Its Assets has fluctuated over the past 5 years, first soared by 232.57% in 2020, then dropped by 27.14% in 2022.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Assets stood at $261.9 million in 2020, then declined by 21.76% to $204.9 million in 2021, then fell by 27.14% to $149.3 million in 2022, then surged by 68.84% to $252.1 million in 2023, then skyrocketed by 81.68% to $457.9 million in 2024.